Actively Recruiting
Study on Predicting Response to Standard First-Line Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Using ctDNA Combined With PET
Led by Fudan University · Updated on 2025-07-17
300
Participants Needed
1
Research Sites
137 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a prospective, multicenter, multi-cohort study of ctDNA combined with PET for predicting the efficacy of standard first-line therapy for patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL).
CONDITIONS
Official Title
Study on Predicting Response to Standard First-Line Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Using ctDNA Combined With PET
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 63 18 years old.
- Newly diagnosed CD20-positive diffuse large B-cell lymphoma (DLBCL) patients including various subtypes defined by 2016 WHO classification.
- Signed informed consent form.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 with expected survival over 12 months.
- At least one measurable lesion: lymph nodes > 1.5 cm or other lesions 63 1.0 cm.
- Adequate major organ function including hematological, liver, renal, pulmonary, and cardiac function as specified.
- Fertile patients agree to use effective contraception during the study and for 120 days after last treatment.
You will not qualify if you...
- Planned to receive short-cycle chemotherapy and radiotherapy.
- Factors affecting compliance including uncontrollable medical, psychological, family, sociological, or geographical conditions.
- Known HIV infection or positive immunoassay.
- Uncontrolled viral infections such as active herpesvirus, acute or chronic active hepatitis B or C (with some exceptions for controlled HBV and HCV).
- Uncontrolled lymphoma infiltration in the central nervous system.
- Pregnant or lactating patients.
- Other serious diseases or medical conditions interfering with study participation.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China, China
Actively Recruiting
Research Team
R
Rong Tao, M.D
CONTACT
W
Wenhao Zhang
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here